Application of rapamycin or salt thereof in preparation of medicine for treating neurodevelopmental disorder diseases and repairing oxidative damage caused by diseases

By using rapamycin to inhibit the mTOR signaling pathway and reduce oxidative stress, the problem of lack of effective drugs in autism treatment has been solved, and new therapeutic effects on autism and the expansion of treatment of neurodevelopmental disorders has been achieved.

CN119055644APending Publication Date: 2024-12-03SHENZHEN MATERNITY & CHILD HEALTHCARE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411338993.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Currently, there is a lack of effective drugs for treating autism, especially due to unclear pathogenesis, long development cycle of new drugs, and lack of clear reports on the application of rapamycin in the field of autism treatment.

Method used

Rapamycin or its salt is used to treat neurodevelopmental disorders and repair oxidative damage caused by diseases, and relieve the pathogenic factors of autism by inhibiting mTOR signaling pathways, reducing inflammation and oxidative stress.

Benefits of technology

Rapamycin shows new capabilities in the treatment of autism, effectively alleviating inflammation and oxidative stress, expanding its medicinal value in the treatment of neurodevelopmental disorders, providing a new source of drugs and shortening the R&D cycle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055644A_ABST
    Figure CN119055644A_ABST
Patent Text Reader

Abstract

The invention discloses application of rapamycin or salt thereof in preparation of drugs for treating neurodevelopment disorder diseases and repairing oxidative damage caused by the diseases, and relates to the technical field of biological medicine and molecular detection biology. The inventor finds that rapamycin does not need to mobilize a damaged endogenous antioxidant system and can induce reduction of the ROS level in vivo through other ways, so that oxidative stress is reduced or eliminated, the antioxidant capacity is exerted, and treatment of developmental nervous system diseases is achieved. In addition, the rapamycin or the salt thereof also has the effect of reducing the inflammation level of a subject. On the premise that inflammation and oxidative stress are key pathogenic factors of autism, a new attempt of rapamycin as an old medicine shows a new ability of treating autism, which shows that rapamycin has wide application prospects and economic values in the field of treatment of neurodevelopment disorders.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of biomedicine and molecular detection biotechnology, and in particular to the use of rapamycin or its salt in the preparation of drugs for treating neurodevelopmental disorders and repairing oxidative damage caused by the diseases. Background Art

[0002] At present, autism, also known as autism spectrum disorder (ASD), is a representative disease of neurodevelopmental disorder. Autism symptoms begin to appear before the child is 3 years old, mainly manifested as social disorders and repetitive stereotyped behaviors. It is generally believed that autism is the result of the combined effects of genetic and environmental factors. The current incidence of autism in children and adolescents is 1 / 59. There are currently no reports of effective drugs. Early detection and early intervention are effective means of preventing and treating the disease. The development of new drugs usually requires a long period of time, especially when the pathogenesis is still unclear. The development of new drugs is like a blind man touching an elephant, which is even more difficult to carry out. New uses of old drugs can greatly shorten the research and development cycle.

[0003] Rapamycin, an autophagy activator, is commonly used as an anti-rejection drug in organ transplantation and tumor treatment. However, there are few clear reports on its use in the treatment of autism, nor are there any reports on its use in reducing inflammation and relieving oxidative stress in autism.

[0004] Recent studies have shown that inflammation and oxidative stress play an important role in the pathogenesis of autism. Since inflammation can increase the production of ROS, and oxidative stress can activate inflammatory pathways. The two work together in the process of neurodevelopment, which can lead to abnormal neural connections, synaptic dysfunction, and changes in neural signaling. Inflammation and oxidative stress transform each other in autism, forming a vicious cycle. Existing studies have shown that maternal immune activation (MIA) may lead to inflammation of the placenta and fetal brain, thereby affecting fetal neurodevelopment, and chronic inflammation of the central nervous system leads to neuronal damage and dysfunction, which are all related to the formation of behavioral symptoms of autism. Reactive oxygen species (ROS) produced by oxidative stress can cause oxidative damage in key brain areas, affecting their neurodevelopment and the balance of neurotransmitters, and then affecting cognition and behavior. Studies have found that people with autism may have defects in the antioxidant defense system, which makes them more susceptible to oxidative damage.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide the use of rapamycin or its salt in the preparation of drugs for treating neurodevelopmental disorders and repairing oxidative damage caused by diseases to solve the above technical problems.

[0007] The present invention is achieved in that:

[0008] In a first aspect, the present invention provides an application of rapamycin or a salt thereof in the preparation of a medicament for treating neurodevelopmental disorders, wherein the neurodevelopmental disorders are selected from the group consisting of intellectual disability, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, specific learning disability, Asperger's syndrome and childhood absence epilepsy (CAE), and one or more neurodevelopmental disorders associated with neuroinflammation.

[0009] In a second aspect, the present invention also provides the use of rapamycin or its salt in the preparation of drugs for repairing oxidative damage.

[0010] The present invention has the following beneficial effects:

[0011] The present invention is based on the abnormal activation of the mTOR signaling pathway in autistic patients, and rapamycin is an effective inhibitor of the pathway. It is found that rapamycin can effectively alleviate the dual adverse physiological states of inflammation and oxidative stress in the body. Under the premise that inflammation and oxidative stress are the key pathogenic factors of autism, rapamycin, as an attempt to use an old drug in a new way, has shown new capabilities in treating autism and has broad medical prospects and economic value for neurodevelopmental disorders.

[0012] Further studies have found that rapamycin does not need to mobilize the already damaged endogenous antioxidant system, but can induce a decrease in ROS levels in the body through other pathways, thereby reducing or eliminating oxidative stress and exerting antioxidant capacity, thereby achieving the treatment of neurodevelopmental disorders.

[0013] The present invention not only provides a new source for preparing drugs for treating neurodevelopmental disorders (especially autism), but also discovers the new medicinal value of rapamycin in the treatment of neurodevelopmental disorders and expands the clinical application scope of rapamycin. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0015] Figure 1 A schematic diagram of the comparison results of the inflammatory factor concentrations in the plasma of normal people and autistic patients provided by the present invention; wherein Figure 1A is a schematic diagram of the concentration results of the cytokine CCL5 in plasma; B is a schematic diagram of the concentration results of the cytokine IL6 in plasma; C is a schematic diagram of the concentration results of the cytokine IL8 in plasma; D is a schematic diagram of the concentration results of the cytokine TNF-α in plasma;

[0016] Figure 2 The present invention provides an enrichment analysis of differentially expressed genes in an autism gene expression dataset GSE18123; wherein Figure 2 A in the middle is the classical pathway enrichment analysis of differentially expressed genes under the core analysis module of IPA software; B is the enrichment analysis of differentially expressed genes for oxidative stress-related pathways. The black numbers above indicate the total number of molecules involved in the biological pathway, among which the proportion of up-regulated molecules in the data set is red, the proportion of down-regulated molecules is green, and the proportion of molecules that do not appear is white;

[0017] Figure 3 This is a schematic diagram of the induction effect of the CCL5 cytokine provided by the present invention on autism-like behavior in mice; wherein Figure 3 A is a heat map of the movement trajectories of test mice with different CCL5 intraperitoneal injection concentrations (0, 40, 80, ng / g mouse) during the first detection stage of the three-box social interaction; B is a schematic diagram of the proportion of the interaction time between the mouse and the stranger mouse S1 during the first detection stage of the three-box social interaction; C is a heat map of the movement trajectories of the test mice during the second detection stage of the three-box social interaction; D is a schematic diagram of the proportion of the interaction time between the mouse and another stranger mouse S2 during the second detection stage of the three-box social interaction; E is a schematic diagram of the bead-burying effect of mice injected with CCL5 intraperitoneally;

[0018] Figure 4 Schematic diagram of mRNA and protein expression levels of representative inflammatory factors in cells treated with different rapamycin concentrations; Figure 4 A is a schematic diagram of the effect of CCL5 gene mRNA expression level; B is a schematic diagram of the effect of IL6 gene mRNA expression level; C is a schematic diagram of the effect of IL8 gene mRNA expression level; D is a schematic diagram of the effect of IL1β gene mRNA expression level; E is a schematic diagram of the effect of TNF-α gene mRNA expression level; F is a schematic diagram of the effect of extracellular CCL5 cytokine secretion level; G is a schematic diagram of the effect of IL6 cytokine intracellular protein expression level;

[0019] Figure 5 This is a schematic diagram of the effect of rapamycin provided by the present invention on inhibiting inflammation; wherein Figure 5A is a schematic diagram showing the intervention effect of rapamycin on the mRNA expression level of CCL5 gene in the LPS-induced HMC3 inflammatory cell model; B is a schematic diagram showing the intervention effect of rapamycin on the mRNA expression level of IL6 gene in the LPS-induced HMC3 inflammatory cell model; C is a schematic diagram showing the intervention effect of rapamycin on the mRNA expression level of IL8 gene in the LPS-induced HMC3 inflammatory cell model; D is a schematic diagram showing the intervention effect of rapamycin on the mRNA expression level of TNF-α gene in the LPS-induced HMC3 inflammatory cell model; E is a schematic diagram showing the intervention effect of rapamycin on the mRNA expression level of IL1β gene in the LPS-induced HMC3 inflammatory cell model; F is a schematic diagram showing the intervention effect of rapamycin on the secretion level of CCL5 cytokine in the LPS-induced HMC3 inflammatory cell model;

[0020] Figure 6 The test result diagram of the in vitro oxidative stress cell model constructed by the present invention; wherein Figure 6 A is a schematic diagram of the changes in intracellular ROS levels in HMC3 cells under treatment with different concentrations of hydrogen peroxide; B is a schematic diagram of the changes in the mRNA expression levels of the Nrf2 gene in HMC3 cells under treatment with different concentrations of hydrogen peroxide; C is a schematic diagram of the changes in the protein expression levels of the Nrf2 gene in HMC3 cells under treatment with different concentrations of hydrogen peroxide; D is a schematic diagram of the mRNA expression level effects of endogenous antioxidant genes in the oxidative stress cell model;

[0021] Figure 7 This is a schematic diagram of the effect of rapamycin provided by the present invention on reducing oxidative stress; wherein Figure 7 A is a schematic diagram of the changes in intracellular ROS levels in HMC3 cells under the treatment of different concentrations of rapamycin; B is a schematic diagram of the changes in intracellular Nrf2 gene protein expression levels in HMC3 cells under the treatment of different concentrations of rapamycin; C is a schematic diagram of the intervention effect of rapamycin on the intracellular ROS level in the oxidative stress cell model; D is a schematic diagram of the intervention effect of rapamycin on the mRNA expression level of the Nrf2 gene in the oxidative stress cell model; E is a schematic diagram of the intervention effect of rapamycin on the protein level of the Nrf2 gene in the oxidative stress cell model; F is a schematic diagram of the intervention effect of rapamycin on the mRNA expression level of endogenous antioxidant genes in the oxidative stress cell model. DETAILED DESCRIPTION

[0022] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0023] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc., 1987). Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0024] In a first aspect, the present invention provides an application of rapamycin or a salt thereof in the preparation of a medicament for treating neurodevelopmental disorders, wherein the neurodevelopmental disorders are selected from one or more of the group consisting of intellectual disability, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, specific learning disability, Asperger's syndrome and childhood absence epilepsy (CAE), and the like, and are neurodevelopmental disorders associated with neuroinflammation.

[0025] The present invention pioneered the use of rapamycin, an mTOR pathway inhibitor, in the treatment of autism, effectively alleviating the body's inflammation and oxidative stress physiology, and removing the pathogenic factors of autism patients from the pathogenesis. The present invention not only provides a new source for the preparation of drugs for the treatment of autism, but also discovers the new medicinal value of rapamycin in the treatment of neurodevelopmental disorders, and expands the clinical application range of rapamycin.

[0026] The chemical formula of rapamycin is C 51 H 79 NO 13 , molecular weight is 914.17, and the structure is shown in Formula 1:

[0027]

[0028] The present invention has no particular limitation on the source of rapamycin, and those skilled in the art can obtain it through commercial channels or extraction. The rapamycin in the present invention has a PubChem chemical substance number of 329830232.

[0029] The preferred rapamycin of the present invention can be extracted from natural substances, or can be artificially synthesized according to the chemical properties of rapamycin. In the embodiment of the present invention, the rapamycin of the present invention is purchased from MedChemExpress, item number #HY-10219, with a purity of 99.94%.

[0030] The salts of rapamycin include but are not limited to rapamycin-40-malate sodium salt.

[0031] The salt of rapamycin is not particularly limited as long as it is a salt permitted as a drug. Examples include salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, and phosphoric acid; salts formed with acetic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptonic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid, oleic acid, pamoic acid, and the like; salts formed with organic acids such as methyl bromide, methyl iodide, etc.; salts formed with halogen ions such as bromide, chloride and iodide; salts formed with alkali metals such as lithium, sodium and potassium; salts formed with alkaline earth metals such as calcium and magnesium; metal salts formed with iron, zinc and the like; salts formed with ammonia; salts formed with organic amines such as triethylenediamine, 2-aminoethanol, 2,2-iminobis(ethanol), 1-deoxy-1-(methylamino)-2-D-sorbitol, 2-amino-2-(hydroxymethyl)-1,3-propanediol, procaine and N,N-bis(phenylmethyl)-1,2-ethylenediamine.

[0032] When rapamycin or a salt thereof has geometrical isomers or optical isomers, the isomers or salts thereof are also included in the scope of the present invention. In addition, when rapamycin or a salt thereof has proton tautomers, the tautomers or salts thereof are also included in the scope of the present invention.

[0033] Rapamycin or its salt may also be in the form of a hydrate or a solvate.

[0034] When rapamycin or its salt exists in polymorphs and polymorph groups (polymorph systems), the polymorphs and polymorph groups (polymorph systems) are also included in the scope of the present invention. Here, the so-called polymorph group (polymorph system) means the crystal form in each stage and the mixture of crystal forms in the whole process when the crystal form undergoes various changes due to the conditions and states such as the production, crystallization, and storage of these crystals (it should be noted that the state also includes the state after formulation).

[0035] Rapamycin or a salt thereof can be prepared according to a common method in the field of biochemistry / organic chemistry. In addition, rapamycin or a salt thereof can also be a commercially available product.

[0036] In a preferred embodiment of the present invention, the neurodevelopmental disorder is autism.

[0037] In a preferred embodiment of the present invention, the drug is used for at least one of the following purposes:

[0038] (1) reduce the level of inflammation in subjects;

[0039] (2) Relieve chronic inflammatory response;

[0040] (3) reduce the oxidative stress effects on subjects;

[0041] (4) inhibiting the activation of the mTOR signaling pathway;

[0042] (5) inhibiting the activation of the inflammatory pathway NF-κB;

[0043] (6) Inhibit the expression of antioxidant genes.

[0044] The mTOR signaling pathway is abnormally activated in autism, and the inflammatory pathway and oxidative stress pathway are also activated. The present invention pioneered the application of the mTOR pathway inhibitor rapamycin in the treatment of autism, and observed significant relief of inflammatory response and oxidative stress effects in cell models.

[0045] The aforementioned inhibition of the expression of antioxidant genes includes but is not limited to inhibition of the mRNA level and protein expression level of antioxidant genes.

[0046] In a preferred embodiment of the present invention, the level of at least one of the following cytokines in the body is reduced:

[0047] CCL5, IL6, IL8, IL1β and TNF-α, including but not limited to reducing the mRNA level or protein expression level of at least one of the above cytokines in the body.

[0048] In a preferred embodiment of the present invention, the antioxidant gene is selected from at least one of the following genes: Nrf2, HO1, NQO1, ABCC2, ME1, TKT, GCLC, GCLM, AKR1C2 and SOD1.

[0049] In a preferred embodiment of the present invention, the drug further comprises a pharmaceutically acceptable excipient.

[0050] The above-mentioned pharmaceutically acceptable excipients include, but are not limited to, fillers, lubricants, disintegrants, binders, glidants, etc.

[0051] In the preferred technical scheme of the present invention, the pharmaceutically acceptable excipients include, but are not limited to, polyvinyl pyrrolidone and its derivatives, polyvinyl alcohol and its derivatives, methyl cellulose and its derivatives, ethyl cellulose and its derivatives, hydroxypropyl cellulose and its derivatives, starch and its derivatives, polyethylene glycol and its derivatives, lactose, sucrose, mannitol, trehalose, sorbitol, dextrin, microcrystalline cellulose, acrylic resin, calcium hydrogen phosphate, calcium stearate, sodium stearyl fumarate, silicon dioxide, titanium dioxide, talc, indigo or a combination thereof.

[0052] In a preferred embodiment of the present invention, the drug is used for oral administration or injection.

[0053] In a second aspect, the present invention also provides the use of rapamycin or a salt thereof in the preparation of a drug for repairing oxidative damage caused by a disease.

[0054] In a preferred embodiment of the present invention, the oxidative damage is oxidative damage in the brain region.

[0055] In a preferred embodiment of the present invention, the disease is a neurodevelopmental disease, and the neurodevelopmental disease is selected from the group consisting of intellectual disability, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, specific learning disability, Asperger's syndrome and childhood absence epilepsy (CAE), and one or more neurodevelopmental disorders associated with neuroinflammation.

[0056] In a preferred embodiment of the present invention, the drug further comprises a pharmaceutically acceptable excipient.

[0057] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0058] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0059] Example 1

[0060] This example provides a qPCR detection method.

[0061] 1. The detection method includes the following steps:

[0062] (1) Extracting total RNA from biological samples;

[0063] (2) A qPCR kit (Evo M-MLV Reverse Transcription Kit II, Code. AG11711; AccurateBiology) was used to remove residual DNA components and then reverse transcribed into cDNA;

[0064] (3) Using cDNA as template, perform qPCR detection.

[0065] In the present invention, gDNA is removed, and the reverse transcription and qPCR amplification systems are shown in Table 1, Table 2 and Table 3:

[0066] Table 1 Reaction system for removing gDNA

[0067]

[0068]

[0069] As mentioned above, in this embodiment, the reaction procedure for removing gDNA (preferably) is:

[0070] Incubate at 42°C for 2 min.

[0071] Table 2 Reverse transcription reaction system (liquid)

[0072] Components and reagent names Usage Table 1 Reaction solution 10μL Evo M-MLV RTase Enzyme Mix 1.0μL RT Primer Mix 1.0μL 5X RTase Reaction Buffer Mix I 4.0μL Deionized water 4.0μL

[0073] In the above, in this embodiment, the reaction procedure of the reverse transcription (preferably) is:

[0074] Incubate at 42°C for 15 min, incubate at 85°C for 5 sec, and store at -20°C;

[0075] Table 3. qPCR amplification system

[0076] Components and reagent names Usage 2×STBR Green Pro Taq HS Premix(Accurate Biology) 10μL Forward primer (10 μM) 0.4μL Reverse primer (10 μM) 0.4μL Table 2 Reverse transcription reaction solution 1.0μL Deionized water 8.2μL

[0077] As mentioned above, in this embodiment, the reaction procedure of the qPCR method amplification is as follows:

[0078] Denaturation at 95 °C for 3 min, denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, extension at 72 °C for 30 s, 45 cycles, and then melting curve analysis, i.e. incubation at 95 °C for 10 s, heating at 65 °C for 1 min, then heating to 97 °C at a rate of 0.3 °C per 15 s, incubation for 1 s, and finally cooling to 37 °C.

[0079] In addition to being used for molecular detection of inflammation and oxidative stress status in autistic patients, the present invention can also be used for molecular detection of other types of biological samples of inflammation or oxidative stress. The results not only help guide the precise treatment of patients, but also effectively avoid the health risks faced by patients due to inflammation or oxidative stress, thereby expanding the scope of application of the present invention.

[0080] Example 2

[0081] Detection of abnormal inflammation levels in autism.

[0082] In this example, blood was collected from 54 typical autistic children and 20 healthy children of age and gender matching. The collected anticoagulated blood was first centrifuged at 3000rpm and 4℃ for 10min, and the supernatant was transferred to a new 1.5ml centrifuge tube. Continue to centrifuge at 13000rpm and 4℃ for 10min to remove insoluble matter. The supernatant is the plasma sample to be tested and frozen at -80℃ for standby use. Using MERCK Milliplex high-throughput multifactor detection technology, the expression levels of inflammatory factors in plasma samples of autistic patients and normal children were detected, and the differences between the two groups were analyzed and compared.

[0083] The results are as follows Figure 1 As shown, the expression of the measured inflammatory factors is upregulated, such as CCL5, IL6, IL8 and TNF-α, the concentration levels in autistic patients are significantly higher than those in normal children, indicating that autistic patients are in an inflammatory state.

[0084] Example 3

[0085] Analysis of inflammatory and oxidative stress pathways in autism.

[0086] The IPA (Ingenuity Pathway Analysis) software provided by QIAGEN was used to perform classical pathway enrichment analysis on the peripheral blood gene chip expression profile dataset GSE18123.

[0087] It was found that mTOR and its downstream pathways were activated ( Figure 2 The black arrow in A) is accompanied by the activation of the inflammatory pathway NF-κB, and its downstream factors IL-6 and IL-8 signaling pathways are also activated. Further analysis of the data set revealed that the reactive nitrogen and reactive oxygen species (ROS) synthesis and oxidative stress effect pathways are also activated in autistic patients ( Figure 2 The abnormal activation of the mTOR pathway in autism has been observed in previous studies. Combined with the oxidative stress effect and the up-regulation of inflammatory factors found in Example 2, it is reasonable to speculate that the mTOR signal plays a regulatory role in autism inflammation and oxidative stress. Therefore, it is considered to treat cells with rapamycin, an inhibitor of mTOR, in the example to observe its intervention effect on the levels of inflammation and oxidative stress.

[0088] Example 4

[0089] Effect of inflammatory factor CCL5 on mouse behavior.

[0090] The induction effect of inflammatory factor CCL5 on autistic-like behaviors was observed at the animal level. 35-day-old normal young mice were used, and CCL5 factor was intraperitoneally injected into the mice according to the following CCL5 doses (mouse recombinant CCL5 / mouse, ng / g): 0, 40, and 80 doses. Their behavioral changes were examined 24 hours later. The social behavior test used a three-box social experiment. The test was divided into two stages: in the first stage, a strange mouse of the same species was placed on one side of the three boxes (S1), and there was only an empty cage on the other side. The test mice that had adapted were allowed to move freely in the three boxes for 10 minutes, and social behaviors were recorded; in the second stage, another strange mouse of the same species (S2) was placed in the empty cage on one side, and the test mice were allowed to move freely in the three boxes for 10 minutes, and social behaviors were also recorded.

[0091] The first phase of the three-box social experiment is the exploration and interaction period of mice with new peers (S1). Figure 3 As shown in A. Compared with the saline control group, the activity trajectories of CCL5-treated mice tended to interact with the empty cage on the other side, and as the CCL5 concentration increased, their interaction with the S1 stranger mouse gradually decreased. Figure 3 As shown in C, mice treated with CCL5 still showed a decrease in interaction with the new stranger mouse S2, and the adverse behavior worsened with increasing concentration. The interaction time with stranger mice in the two stages was counted separately, and it was found that the CCL5 inflammatory factor caused the mice to explore the interaction time of new peers ( Figure 3 (B, D).

[0092] In addition, this example also tests behaviors such as bead burying that reflect stereotyped and narrow interests. Before the experiment begins, lay 5 cm thick corn cob bedding in the empty mouse cage and level it. Figure 3 As shown in E, 20 glass beads with a diameter of 15 mm were placed in 4 rows, with 5 beads in each row. Then the test mouse was placed in the cage, and the number of buried glass beads was counted after 30 minutes. The number of buried beads was calculated according to the following statistical standards: 1 bead was considered when the buried volume was >50%, 0.5 bead was considered when the buried volume was 25-50%, and 0 bead was considered when the buried volume was <25%. Figure 3 The results in middle E show that CCL5-treated mice did not show excessive stereotyped behavioral tendencies of burying glass beads.

[0093] The results of Example 4 revealed that CCL5, as an inflammatory factor, showed a significant tendency to impair social behavior.

[0094] Example 5

[0095] This example detects the effective concentration of rapamycin to reduce inflammation levels and its effect on the expression levels of inflammatory factors.

[0096] Example 4 has shown that the levels of inflammatory factors are indeed closely related to autism-like behaviors.

[0097] The HMC3 cell line (CRL-3304) is a primary microglia derived from human fetal brain. It not only retains the characteristics of microglia, but is also transformed into an immortalized cell line, making it very suitable for the construction of in vitro cell models of degenerative diseases. Glial cells are inflammatory factor-secreting cells that reside in the brain and can change the level of inflammation in the brain. Through the release of inflammatory factors, they cause neuroinflammation, leading to neuronal damage and loss.

[0098] Therefore, this example detects the effect of rapamycin on the gene expression of inflammatory factors in glial cells (taking HMC3 cells as an example). HMC3 cells were plated in a 6-well plate and cultured with MEM medium (Gibco, 11095-080) containing 10% FBS and 1mM sodium pyruvate, and incubated overnight at 37°C, 5% CO2 in an incubator. After the cell confluence reached 90%, HMC3 cells were treated with different concentrations of rapamycin (0, 50, 100, 200, 400, 600nM) for 48h, and the cell pellets were collected to detect the expression of intracellular inflammatory factors. Specifically, after digestion with 0.25% trypsin and washing with PBS, the cell pellets were collected by centrifugation at 500×g for 5min. RNA was extracted using the NucleoSpin RNA Plus kit (Cat. 740984.50, MACHEREY-NAGEL), and the obtained RNA samples were subjected to the reaction systems of Table 1 and Table 2, and then the amplification reaction solution was prepared as shown in Table 3. Finally, the changes in the transcription levels of inflammatory factors such as CCL5, IL6, IL8, IL1β, and TNF-α were detected by real-time fluorescence quantitative PCR (qPCR) instrument, and their primer sequence information is shown in SEQ ID NO.1-SEQ ID NO.10.

[0099] The primer sequence information is as follows:

[0100]

[0101]

[0102] qPCR quantitative detection was performed using the kit provided in Example 1 of the present invention, and the results were as follows Figure 4 As shown in the figure, with the increase of rapamycin concentration, the expression of intracellular inflammatory factors was inhibited, and the expression levels of the five inflammatory factors detected were all decreased. Taking into account the reasonable dosage and anti-inflammatory effect of the drug, 200-400nM rapamycin has significant therapeutic effect, and 400nM is preferred for better anti-inflammatory treatment effect. At this concentration, cells grow well and no toxic side effects of the drug are observed.

[0103] It can be seen that for HMC3 cells, 400nM rapamycin concentration is a more appropriate therapeutic concentration.

[0104] Continue to detect changes in inflammatory factor protein levels.

[0105] An ELISA detection kit (Cat. No. DRN00B; R&D Systems) was used to evaluate the effect of rapamycin on the concentration of CCL5 inflammatory factors released into the extracellular space. The specific operation can be carried out according to the product instructions.

[0106] Immunoblotting was used to detect changes in the level of intracellular inflammatory factor IL-6 protein. Specifically, the collected HMC3 cell pellet was added with 10 times the volume of RIPA lysis buffer (Cat. No. 89900; Thermo Scientific) and an appropriate amount of protease inhibitor (200×, Cat. No. 539134; Millipore). Ultrasonic disruption was performed until the cells were completely lysed, incubated on ice for 10 min, centrifuged at 13600 rpm at 4°C for 10 min, and the supernatant was collected and transferred to another EP tube. The protein concentration was detected by Bradford method. The 12-230 kDa separation kit (SM-W004; ProteinSimple) was used to perform protein capillary electrophoresis separation using the WES system, and IL-6 antibody (ab9324; Abcam) and HRP-labeled secondary antibody (anti-rabbit / mouse DM-001 / DM-002; ProteinSimple) were used for immunochromatography, and GAPDH antibody (NB300-325; NOVUS) was used as the internal reference antibody. The Compass analysis software provided by the WES system was used to calculate the band optical density, and then the expression level of inflammatory factors was quantitatively analyzed.

[0107] As the concentration of rapamycin increases, the level of CCL5 protein released into the extracellular space is detected by ELISA, such as Figure 4 The expression of IL6 in the cells was further detected by Western blotting. Figure 4 As shown in G in Figure 2, its protein level was also significantly downregulated. These results indicate that rapamycin can effectively reduce the level of inflammatory factors. Preferably, a rapamycin concentration of 400 nM is a more appropriate therapeutic concentration. Figure 4 As shown in G, at this concentration, the expression of intracellular inflammatory factor proteins was significantly inhibited.

[0108] It can be seen that the present invention can effectively detect five inflammatory cytokines. The expression changes of these factors are consistent with their protein levels, which fully reflects the changes in the inflammatory state inside the cells.

[0109] The above test results show that rapamycin can inhibit the expression of inflammatory factors, and this inhibitory effect is achieved by reducing the transcription level, which in turn leads to a decrease in the corresponding protein level. 400nM rapamycin showed a good anti-inflammatory therapeutic effect. In addition, the detection primers designed in this embodiment can not only successfully analyze the expression level of intracellular inflammatory factor mRNA, but also because its expression trend is consistent with the change trend of protein level, these primers can also be used as a tool to predict changes in inflammatory factor protein levels.

[0110] Example 6

[0111] This example demonstrates that rapamycin can effectively inhibit the inflammatory response of microglia.

[0112] Lipopolysaccharide (LPS) was used to construct an inflammatory cell model. LPS is a currently recognized inflammatory inducer that can activate the host's immune system and lead to an inflammatory response. In this embodiment, LPS (#14011; Cell Signaling) with a final concentration of 2 μg / ml was used to induce an inflammatory cell model (taking HMC3 cells as an example). Specifically, HMC3 cells were plated on a 6-well plate and cultured with MEM medium containing 10% FBS and 1mM sodium pyruvate, and incubated overnight at 37°C and 5% CO2 in an incubator. After the cell confluence reached 90%, drug treatment was performed. The experiment was divided into four groups: 1) no drug group; 2) LPS group (2μg / ml LPS was administered for 48h); 3) rapamycin group + LPS (2μg / ml LPS and 400nM rapamycin were administered simultaneously for 48h); 4) rapamycin group (400nM rapamycin was administered for 48h). After the cell culture was completed, the cells were digested with 0.25% trypsin, washed with PBS, centrifuged at 500×g for 5 min, and the cell pellets were collected. RNA was extracted using the NucleoSpin RNA Plus Kit (Cat.740984.50, MACHEREY-NAGEL), and the obtained RNA samples were subjected to the reaction systems of Tables 1 and 2, and then the amplification reaction solution was prepared according to Table 3, and finally the changes in the transcription levels of inflammatory factors such as CCL5, IL6, IL8, IL1β, and TNF-α were detected by real-time fluorescence quantitative PCR (qPCR) instrument, and their primer sequence information is shown in SEQ ID NO.1-SEQ ID NO.10.

[0113] qPCR quantitative results are as follows Figure 5 As shown in the figure, after LPS is added to the cells, the inflammatory pathway is activated, which is manifested by a significant increase in the expression levels of various inflammatory factors in the body. At this time, if rapamycin molecules are added for co-incubation, the expression of various inflammatory factors in the cells is downregulated, showing an anti-inflammatory effect ( Figure 5 AE in ).

[0114] The mouse behavioral test in Example 4 showed that the injected free inflammatory factor CCL5 can induce autism-like behaviors in normal mice, especially abnormal social behaviors. Therefore, this example uses the CCL5 ELISA detection kit (Cat. No. DRN00B; R&D Systems) to evaluate the effect of rapamycin on the concentration of CCL5 inflammatory factors released into the extracellular space by the inflammatory cell model. The specific operation can be carried out according to the product instructions.

[0115] The results of the CCL5 secretion test were as follows: Figure 5 As shown in Figure F, rapamycin can significantly reverse the increase in CCL5 concentration in the culture medium caused by LPS. Figure 5 Middle A and Figure 5 The results in Figure F show that rapamycin not only leads to a decrease in CCL5 expression, but also causes a decrease in the concentration level of CCL5 secreted into the extracellular space, demonstrating excellent therapeutic potential.

[0116] The above test results show that rapamycin effectively alleviates the inflammatory state of cells, can curb the induction of autistic behaviors by inflammatory factors, and reduce the potential risk of autism, thus showing the potential for treating autism. The designed detection primers successfully analyzed the expression of inflammatory factor mRNA levels in cells, which can be used to predict changes in the inflammatory level in samples.

[0117] Example 7

[0118] In this example, an oxidative stress cell model was established and the expression of a series of antioxidant genes was detected.

[0119] The method for constructing the oxidative stress cell model is as follows:

[0120] HMC3 cells of appropriate concentration were inoculated in 6 cm cell culture dishes and cultured in MEM medium containing 10% FBS and 1 mM sodium pyruvate, and incubated overnight at 37 ° C in a 5% CO2 incubator. After the cell confluence reached 90%, HMC3 cells were treated with different concentrations of hydrogen peroxide (0, 50, 100, 200, 400 μM) for 24 h to induce an in vitro oxidative stress cell model. After the cell culture was completed, the cells were digested with 0.25% trypsin and the cell pellet was collected. The cells were resuspended in serum-free MEM medium containing 5 μM DCFH-DA (2,7-dichlorofluorescein diacetate, a ROS-specific fluorescent probe) and incubated at 37 ° C for 20 minutes. The cells were centrifuged at 500 × g, washed twice with PBS buffer, and finally the fluorescence intensity was detected under 488 nm excitation light.

[0121] Test results such as Figure 6As shown in Figure A, as the concentration of hydrogen peroxide increases, the level of intracellular ROS gradually increases. 200 μM hydrogen peroxide treatment can increase the level of intracellular ROS by 50%, indicating that the cells are in a state of oxidative stress. With the activation of the endogenous antioxidant system, we detected that both the mRNA and protein levels of Nrf2 were upregulated ( Figure 6 In Figures B and C), the transcription level of the Nrf2 gene was detected using primer sequences shown in SEQ ID NO.11 and SEQ ID NO.12, and the reaction solution was prepared according to Tables 1, 2 and 3; the protein level was detected using Nrf2 antibody (#12721; Cell Signaling), and protein electrophoresis was performed using the WES system (ProteinSimple).

[0122] Nrf2 is a hub molecule of the body's antioxidant defense system. As an important redox-sensitive transcription factor, it maintains the redox homeostasis of cells by regulating the expression of many endogenous antioxidant molecules, thereby controlling the body's ROS level and preventing its excessive accumulation.

[0123] The detection primer sequences of Nrf2 and a series of downstream antioxidant target genes are as follows:

[0124]

[0125]

[0126] In this oxidative stress model example, a series of antioxidant target genes downstream of Nrf2 were activated and expressed, and the results were as follows: Figure 6 As shown in D, the expressions of the nine selected antioxidant genes were significantly upregulated to cope with the oxidative stress effects in vivo. Figure 6 "Auto-fluo" in A is the autofluorescence intensity value of HMC3 cells, which is negligible compared to the luminescence of DCFH-DA. Due to the toxicity of hydrogen peroxide itself, when its concentration exceeds 400μM, cells under the microscope have begun to die in large numbers.

[0127] It can be seen that for HMC3 cells, 200 μM hydrogen peroxide treatment concentration is a more appropriate concentration for oxidative stress modeling. In addition, the present invention can effectively detect 9 antioxidant genes, and the changes in their expression fully reflect the changes in the endogenous antioxidant capacity of cells.

[0128] Example 8

[0129] This example demonstrates that rapamycin can effectively reduce the level of cellular oxidative stress.

[0130] Taking HMC3 cells as an example, different concentrations of rapamycin were used to act on HMC3 cells. After 48 hours of treatment, the intracellular ROS level was detected according to the method in Example 7.

[0131] Depend on Figure 7 As shown in Figure A, with the increase of rapamycin concentration, the intracellular ROS level gradually decreased in a dose-dependent manner, indicating that rapamycin can effectively reduce intracellular oxidative tension, and the 400nM rapamycin dose showed the lowest intracellular ROS level.

[0132] However, the expression of Nrf2 was detected by immunoblotting (according to the method in Example 7). Figure 7 As shown in B, it was found that the protein expression of Nrf2 was not significantly affected under different rapamycin concentrations.

[0133] The oxidative stress cell model in Example 7 was further used to observe the intervention effect of rapamycin on oxidative stress cells (taking HMC3 cells as an example). The groups were divided into the following: 1) No drug group; 2) Oxidative stress group (200 μM hydrogen peroxide treatment for 24 hours); 3) Hydrogen peroxide + rapamycin group (400 nM rapamycin treatment for 48 hours and 200 μM hydrogen peroxide co-incubation for 24 hours). For the above two groups, hydrogen peroxide was added to the culture medium 24 hours before collecting the cells. 4) Rapamycin group (400 nM rapamycin administration treatment for 48 hours). According to the method in Example 7, the intracellular ROS levels of the above four groups of cells were detected.

[0134] The results are as follows Figure 7 As shown in C, after hydrogen peroxide stimulated the cells, the intracellular ROS level increased significantly, and after intervention with rapamycin molecules, the intracellular ROS level decreased significantly, indicating that the oxidative stress effect was effectively alleviated by rapamycin. Whether this is related to the improvement of cellular antioxidant capacity, qPCR was used to detect the expression of the Nrf2 gene, and its detection primers are shown in SEQ ID NO.11 and SEQ ID NO.12.

[0135] The results are as follows Figure 7 As shown in D, the addition of hydrogen peroxide did cause an upregulation of Nrf2 expression, indicating that the Nrf2 antioxidant system was activated by hydrogen peroxide, but its expression was not further increased by the addition of rapamycin, but was inhibited. Further detection of Nrf2 protein expression by immunoblotting showed the same trend of change. The intracellular Nrf2 protein level did not increase with the addition of rapamycin, as shown in Figure 7 As shown in E, it shows a certain degree of suppression. The expression of a series of target genes was detected by qPCR. The specific primer sequence information is shown in SEQ ID NO.13-SEQ ID NO.30. The reaction solution was configured according to Tables 1, 2 and 3. The results are shown in Figure 7 As shown in F, the expressions of its downstream antioxidant target genes were all inhibited.

[0136] Therefore, rapamycin can avoid mobilizing the body's endogenous antioxidant system and induce a decrease in ROS in the body through other pathways, thereby reducing the level of oxidative stress in the body.

[0137] It can be seen that rapamycin can effectively reduce the level of ROS in the body and resist oxidative stress. Importantly, this process does not require the mobilization of the patient's endogenous antioxidant system, which may have been damaged and urgently needs to be repaired, and is of great benefit to the patient's rapid response and recovery after oxidative damage. The designed detection primers can successfully analyze the changes in the mRNA levels of antioxidant genes in cells and are suitable for the evaluation of oxidative stress effects in biological samples.

[0138] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of rapamycin or its salt in the preparation of a drug for treating neurodevelopmental disorders, characterized in that: The neurodevelopmental disorder is selected from the group consisting of intellectual disability, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, specific learning disability, Asperger's syndrome and childhood absence epilepsy (CAE), and one or more neurodevelopmental disorders associated with neuroinflammation.

2. The use according to claim 1, characterized in that: The neurodevelopmental disorder is autism.

3. The use according to claim 1, characterized in that: The drug is used for at least one of the following purposes: (1) reduce the level of inflammation in subjects; (2) Relieve chronic inflammatory response; (3) reduce the oxidative stress effects on subjects; (4) inhibiting the activation of the mTOR signaling pathway; (5) inhibiting the activation of the inflammatory pathway NF-κB; (6) Inhibit the expression of antioxidant genes.

4. The use according to claim 3, characterized in that: Reduce the level of at least one of the following cytokines in the body: CCL5, IL6, IL8, IL1β and TNF-α.

5. The use according to claim 3, characterized in that: The antioxidant gene is selected from at least one of the following genes: Nrf2, HO1, NQO1, ABCC2, ME1, TKT, GCLC, GCLM, AKR1C2 and SOD1.

6. The use according to any one of claims 3 to 5, characterized in that: The drug also includes pharmaceutically acceptable excipients.

7. The use according to claim 6, characterized in that: The drug is used for oral administration or injection.

8. Use of rapamycin or its salt in the preparation of a drug for repairing oxidative damage caused by a disease.

9. The use according to claim 8, characterized in that: The oxidative damage is oxidative damage in the brain region; Preferably, the disease is a neurodevelopmental disease, and the neurodevelopmental disease is selected from one or more neurodevelopmental disorders associated with neuroinflammation in the group consisting of intellectual disability, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, specific learning disability, Asperger's syndrome and childhood absence epilepsy (CAE).

10. The use according to any one of claims 8 to 9, characterized in that: The drug also includes pharmaceutically acceptable excipients.